<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347399</url>
  </required_header>
  <id_info>
    <org_study_id>AvastinTFD</org_study_id>
    <nct_id>NCT00347399</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration</brief_title>
  <official_title>Effects of Intravitreal Injection of Bevacizumab in Combination With Verteporfin Photodynamic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if of combination therapy of intravitreal
      bevacizumab 4 days after the application of photodynamic therapy could improve the visual
      outcomes of patients with neovascular age related macular degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The neovascular age related macular degeneration(AMD) is a important cause of legal blindness
      in adults older than 50 years. Currently the treatment is photodynamic therapy that offer
      stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been
      reported effective used as intravenous injection for AMD. But serious side effects have been
      reported with the use of this drug in oncologic patients. The intravitreal use has been
      reported in limited case reports and safety and efficacy should be determined. The purpose of
      this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD 4 days after
      photodynamic therapy with verteporfin
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <completion_date>June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity improvement at 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness improvement at 6 months</measure>
  </secondary_outcome>
  <enrollment>25</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab intravitreal injection</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>verteporfin photodynamic therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        55 years old neovascular Age related acular degeneration subfoveolar neovascular membrane
        best corrected visual acuity better than 20/200 snellen (1.0 logMAR)

        Exclusion Criteria:

          -  Previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary
             artery disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <role>Study Director</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Dalma Weizhaus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dalma Jose Dalma-Weizhaus</last_name>
    <phone>10841400</phone>
    <phone_ext>1171</phone_ext>
    <email>draojitos26@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Luis Sanchez Bulnes</name>
      <address>
        <city>Mexico city</city>
        <state>DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Quiroz-Mercado, MD</last_name>
      <phone>525510841400</phone>
      <email>retinamex@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maura L Abraham Marin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.</citation>
    <PMID>16156152</PMID>
  </reference>
  <verification_date>June 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>June 30, 2006</last_update_submitted>
  <last_update_submitted_qc>June 30, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2006</last_update_posted>
  <keyword>macular degeneration</keyword>
  <keyword>antibodies</keyword>
  <keyword>angiogenesis inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

